Danaher (DHR) Is Up 5.3% After Q1 Beat, EPS Hike And Biotech Momentum - What's Changed
Danaher (DHR) reported strong Q1 2026 results, exceeding earnings expectations and raising its full-year adjusted EPS guidance. The company saw 7% core revenue growth in its Biotechnology segment and is advancing its US$9.90 billion Masimo acquisition, reinforcing its position in diagnostics, bioprocessing, and advanced filtration. These developments support the investment thesis of steady, consumables-driven demand and disciplined capital allocation for Danaher, with the Masimo acquisition remaining a key near-term catalyst.
Henry Schein Names William K “Dan” Daniel as Chairman of the Board
Henry Schein has appointed William K “Dan” Daniel as the new independent chairman of its board, effective May 21, 2026. Daniel succeeds Stanley M Bergman, who is transitioning to chairman emeritus after 44 years of service. Daniel brings extensive executive leadership experience from the healthcare and industrial sectors, including his previous role at Danaher Corp where he oversaw its dental portfolio.
Henry Schein Elects William K. “Dan” Daniel as Independent Chairman of the Board, Succeeding Stan Bergman After 44 Years
Henry Schein, Inc. has announced the election of William K. “Dan” Daniel as the new Independent Chairman of the Board, effective May 21, 2026. This appointment follows the retirement of long-serving Chairman Stanley M. Bergman, who has been named Chairman Emeritus after 44 years with the company. The transition occurs as Henry Schein continues to implement its strategy to become a leading integrated solutions platform in healthcare, with Daniel bringing extensive executive experience from Danaher Corporation to his new role.
Henry Schein Names New Board Chairman
Henry Schein, Inc. has announced the election of William K. "Dan" Daniel as the new Independent Chairman of the Board, effective May 21, 2026. He succeeds Stanley M. Bergman, who retired after 44 years and was named Chairman Emeritus. Mr. Daniel brings extensive experience from the healthcare and industrial sectors, including a significant tenure at Danaher Corporation, and will focus on continuing the company's growth strategy.
Henry Schein appoints William Daniel as independent chairman
Henry Schein, Inc. has announced the election of William K. Daniel as its Independent Chairman of the Board, effective May 21, 2026. Daniel succeeds Stanley M. Bergman, who retired after 44 years and was named Chairman Emeritus. Daniel joined the board in May 2025 and previously served as Executive Vice President at Danaher Corporation, overseeing its dental portfolio.
Henry Schein Announces the Election of William K. “Dan” Daniel as Independent Chairman of the Board
Henry Schein, Inc. announced the election of William K. “Dan” Daniel as Independent Chairman of the Board, effective May 21, 2026. Mr. Daniel succeeds Stanley M. Bergman, who retired after 44 years and was named Chairman Emeritus. Daniel brings extensive healthcare and industrial leadership experience, including 14 years at Danaher Corporation, and will build upon Bergman's legacy while supporting the company's growth strategy.
Research Tools & Consumables Stocks Q1 Results: Benchmarking Danaher (NYSE:DHR)
The article reviews the Q1 earnings of research tools & consumables stocks, highlighting mixed results across the sector. Danaher (NYSE:DHR) reported revenues slightly below expectations, leading to an 11.4% stock decline. In contrast, Waters Corporation (NYSE:WAT) significantly outperformed, while Revvity (NYSE:RVTY), Thermo Fisher (NYSE:TMO), and Avantor (NYSE:AVTR) also presented varying financial outcomes and market reactions.
Danaher Corp. stock (US2358511028): earnings beat keeps focus on life sciences recovery
Danaher Corp. reported a first-quarter 2026 earnings beat, exceeding Wall Street expectations, though revenue growth remained modest. The company's performance keeps investor attention on the recovery pace of its life sciences and diagnostics segments, which are crucial for its long-term growth. Danaher's diversified portfolio and strategic management system position it to capitalize on healthcare and scientific research trends, but near-term share price volatility reflects ongoing market sentiment concerns about demand in key end markets.
Thermo Fisher’s New Sweden Lab Deepens Role In Global Drug Development
Thermo Fisher Scientific has opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, bolstering its global drug development services, especially for complex modalities like antibodies and cell therapies. This move aims to deepen its role as a partner to pharmaceutical and biotech companies, expanding its reach in the Nordic region and reinforcing its competitive position against peers. Despite recent share price volatility and debt concerns, the company is investing in core drug development services, and investors should monitor the lab's utilization and its impact on long-term customer relationships.
Fortive stock (US34959J1088): earnings update keeps focus on portfolio shift and recurring revenue
Fortive, an industrial technology group, recently reported its quarterly results, highlighting its ongoing portfolio transformation towards software and recurring revenue. The company, a spin-off from Danaher, focuses on measurement, automation, and safety solutions, combining hardware with software and data services. This strategy aims to balance cyclical industrial demand with more stable subscription and service revenues, driven by an operating system based on continuous improvement and investment in high-growth niches.
DexCom Inc. stock outperforms competitors on strong trading day
DexCom Inc. stock exhibited a strong performance on a recent trading day, closing higher and outperforming its competitors. The stock also surpassed the S&P 500 in daily gains.
Discipline and Rules-Based Execution in DHR Response
This article provides an AI-generated analysis for Danaher Corporation (NYSE: DHR), highlighting divergent sentiment across horizons and elevated downside risk. It outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels for each, based on multi-timeframe signal analysis.
Should Higher Impairments and AI Investments Shape a New Capital Allocation Playbook for Charles River (CRL)?
Charles River Laboratories (CRL) reported first-quarter results showing modest revenue growth but a net loss and increased impairments, alongside a raised full-year GAAP EPS guidance. The company is actively reshaping its business through significant investments in AI-enabled digital pathology and cell therapy testing collaborations, aiming for improved efficiency and margin recovery. While these strategic shifts indicate a focus on higher-value services, investors are encouraged to consider the impact of rising cancellations and a book-to-bill ratio below 1x on the benefits of these initiatives.
Eagle Capital Management Bet on Danaher (DHR) for Its Mid-Teens EPS Growth
Eagle Capital Management has invested in Danaher Corporation (DHR), a life sciences company, anticipating mid-teen EPS growth. The firm believes Danaher's current depressed valuation, strong market share, and potential acceleration from AI in biopharma research present a significant opportunity. Despite recent volatility and challenges, Eagle Capital sees future growth as earnings stabilize and improve.
Danaher stock (US2358511028): spin-off, diagnostics focus and what the latest numbers reveal
Danaher is strategically refocusing its portfolio on life sciences and diagnostics after spinning off Veralto in 2023. Recent financial updates provide insights into the company's performance, including its ability to navigate market demand through its Danaher Business System and its recurring revenue model based on consumables and services. The article highlights Danaher's core business in bioprocessing and diagnostics, its geographical revenue mix, and factors affecting its growth and profitability.
DANAHER ANNOUNCES QUARTERLY DIVIDENDS
Danaher Corporation has announced its quarterly dividends. Quantisnow Plus members were alerted about this press release shortly after its publication. The article also mentions related SEC filings and insider trading activity concerning Danaher.
Barclays (DJP) sells $2.63M AutoCallable Contingent Coupon Notes, 9.70% p.a.
Barclays Bank PLC is offering $2.63 million in AutoCallable Contingent Coupon Notes, set to mature on May 23, 2029, with a contingent annual coupon rate of 9.70%. These notes are linked to the performance of four equity securities: BDX, GEHC, ZBH, and DHR, and investors' principal repayment at maturity is subject to the performance of the least performing reference asset. The offering includes potential risks such as loss of principal, dependence on Barclays' creditworthiness and the U.K. Bail-in Power, and limited upside potential compared to direct equity ownership.
Danaher (NYSE: DHR) director awarded RSUs and long-dated stock options
Danaher Corporation director A. Shane Sanders was awarded 680 restricted stock units (RSUs) and 1,699 director stock options on May 15, 2026, as part of his compensation. The RSUs are payable in common stock, increasing his direct holdings to 5,914.088 shares, and vest on the earlier of the first anniversary of the grant or the next annual shareholder meeting. The stock options have an exercise price of $161.91 per share and expire on May 15, 2036, linking a portion of his compensation to the company's long-term stock performance.
Danaher Corp. stock outperforms competitors on strong trading day
Shares of Danaher Corp. (DHR) rose 2.44% to $171.12 on Wednesday, outperforming the broader stock market. This marks the third consecutive day of gains for the stock, as the S&P 500 Index and Dow Jones Industrial Average also experienced significant increases.
Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead?
Danaher Corporation's Biotechnology segment shows strong performance, with core revenues increasing 7% in Q1 2026 due to sustained momentum in bioprocessing and robust demand from pharmaceutical customers. Despite some headwinds in medical filtration and declining equipment demand, the company projects mid-single-digit core revenue growth for the segment in Q2 2026. Danaher's shares have declined recently, and its valuation is above the industry average, but its 2026 earnings estimate has seen an increase.
Danaher (NYSE: DHR) SVP uses 281 shares for tax withholding, retains 8,291
Danaher Corporation SVP Georgeann Couchara disposed of 281 common shares to satisfy tax withholding obligations. This non-market transaction was reported on a Form 4 filing, with the shares valued at $161.91 each. Following this transaction, Couchara directly retains 8,291 shares of Danaher common stock.
Danaher Announces Quarterly Dividends
Danaher Corporation has announced its quarterly dividends. The announcement was made via a press release and alerted to Quantisnow Plus members shortly after publication. Quantisnow, a market data platform, delivered this insight to its users.
Danaher Announces Quarterly Dividends
Danaher Corporation has announced its quarterly dividends. The announcement was made originally via a press release and was quickly picked up by Quantisnow, a real-time market data platform that alerts its members to such financial news. This information is critical for investors tracking DHR.
Danaher Announces Quarterly Dividends
Danaher Corporation (DHR) has announced its quarterly dividends. Quantisnow Plus members received an alert about this announcement shortly after its publication. The article also highlights recent insider transactions involving several directors and an SVP, detailing changes in their share ownership.
Danaher (NYSE: DHR) director Teri List granted RSUs and stock options as board compensation
Danaher Corporation director Teri List received new equity awards as part of her board compensation, including 680 restricted stock units (RSUs) and a director stock option for 1,699 shares with an exercise price of $161.91. This transaction increased her direct holdings to 21,470.399 common shares and 1,699 options. The RSUs vest in one year or at the next annual shareholder meeting, with shares issued later, while the options expire in 2036.
Thermo Fisher Scientific expands global biobank leadership through strategic collaboration with PRECISE-SG100K Singapore to advance population-scale proteomics
Thermo Fisher Scientific is collaborating with Precision Health Research, Singapore (PRECISE) to support its PRECISE-SG100K study, a major population-scale biobank initiative. This partnership focuses on advancing population-scale proteomics to improve disease detection, prevention, and personalized care. The collaboration will integrate Thermo Fisher's Olink® Proximity Extension Assay platforms and Orbitrap Astral mass spectrometry system with Seer’s Proteograph® Product Suite to provide comprehensive proteomic analysis, enabling the translation of biological data into new disease mechanisms and biomarker insights.
Danaher Corp. stock (US2358511028): insider awards highlight leadership confidence after guidance li
Danaher Corp. (DHR) raised its 2026 guidance after a stronger-than-expected first quarter, leading to a more constructive sentiment among investors despite the stock trading below early-year levels. Recent equity awards to board members Teri List and Linda Filler, though part of routine compensation, signal their long-term alignment with shareholders. The company's core business model focuses on life science tools, diagnostics, and industrial technologies, emphasizing recurring revenues and strategic acquisitions.
Danaher (NYSE: DHR) director Linda Filler receives stock and option grants
Danaher Corporation director Linda Filler has received new equity awards, including 680 shares of common stock as restricted stock units and 1,699 director stock options with an exercise price of $161.91 per share. These awards, detailed in a Form 4 filing, increase her equity holdings in the company. The restricted stock units vest on the earlier of the first anniversary of the grant date or the next annual shareholder meeting, while the options expire in May 2036.
[Form 4] DANAHER CORP /DE/ Insider Trading Activity
Danaher Corporation director Raymond C. Stevens reported insider trading activity involving equity awards. He received 680 restricted stock units (RSUs) and director stock options for 1,699 common shares with an exercise price of $161.91. These awards, detailed in a Form 4 filing, contribute to his direct holdings of 13,728.286 common shares and 1,699 stock options.
Danaher (NYSE: DHR) awards director Zerhouni RSUs and stock options
Danaher Corporation director Elias A. Zerhouni reported new equity awards, including 680 restricted stock units and 1,699 director stock options with a $161.91 exercise price. These grants were made on May 15, 2026, and are compensation-related rather than market trades. Following these transactions, Zerhouni holds 43,186.282 shares directly and 7,500 shares indirectly through an LLC.
Alan G. Spoon (DHR) awarded RSUs and stock options in new Danaher Form 4
Danaher Corporation director Alan G. Spoon reported new equity awards in a recent Form 4 filing. He received 680 restricted stock units (RSUs) and a grant of 1,699 director stock options with an exercise price of $161.91 per share. Following these transactions, Spoon directly holds 124,773.689 common shares and indirectly holds 8,700 shares through an LLC.
Danaher Corp. stock outperforms competitors on strong trading day
Danaher Corp. (DHR) shares increased by 1.94% to $167.04 on a day when the broader stock market, including the S&P 500 Index and Dow Jones Industrial Average, experienced declines. This marks the second consecutive day of gains for Danaher's stock, demonstrating an outperformance compared to its competitors.
Danaher Stock Forecast 2026: The Bioprocessing Equipment Cycle Has Started and Few Are Watching
Danaher (DHR) delivered a strong Q1 2026 earnings beat, with bioprocessing equipment orders growing over 30% year-over-year, signaling the start of a multiyear investment cycle. This positive news, along with expanding operating margins and a pending acquisition of Masimo, positions the stock for significant upside, according to analyst consensus and TIKR's valuation model. Despite the stock trading near a 52-week low, most analysts rate DHR as a Buy or Outperform, with a mean price target well above its current price.
Danaher Corp. stock (US2358511028): restructuring after spin-off, new focus on life sciences
Danaher Corp. is actively reshaping its portfolio, emphasizing life sciences and diagnostics following the 2023 spin-off of Veralto. The company's strategy involves continuous innovation, targeted acquisitions, and a focus on recurring revenue streams from consumables and services, supported by its Danaher Business System. While the company aims to capitalize on long-term healthcare trends, investors should consider risks such as demand cycles in bioprocessing, integration challenges of acquisitions, and regulatory complexities.
Danaher Corp. stock outperforms competitors on strong trading day
Danaher Corp. (DHR) shares increased by 1.20% to $163.86 on Monday, outperforming a mixed stock market day where the Dow Jones rose and the S&P 500 fell. This rise ended a six-day losing streak for the company's stock.
Northwestern Mutual Wealth Management Co. Acquires 186,584 Shares of Danaher Corporation $DHR
Northwestern Mutual Wealth Management Co. significantly increased its stake in Danaher Corporation (NYSE:DHR) by over 300% in the fourth quarter, purchasing an additional 186,584 shares to bring its total holding to 248,020 shares valued at approximately $56.8 million. This acquisition, alongside increased positions from several other institutional investors, highlights strong professional ownership interest, with institutions now owning 79.05% of the company's stock. Danaher also reported better-than-expected quarterly earnings and announced a quarterly dividend, while analysts maintain a "Moderate Buy" rating for the stock.
Natera, Inc. (NTRA) Investor Outlook: Exploring A 39.99% Upside With Strong Buy Ratings
Natera, Inc. (NTRA), a key player in healthcare diagnostics with a $26.69 billion market cap, shows strong long-term growth prospects despite current losses. Analysts project a potential upside of nearly 40% with an average target price of $260.89, supported by impressive revenue growth of 38.80% and overwhelmingly positive analyst sentiment. The company, known for its innovative molecular testing services, is heavily investing in future growth with 17 buy ratings and no sell ratings.
Danaher stock (US2358511028): earnings momentum and dividend in focus for US investors
Danaher (DHR) reported higher first-quarter 2026 revenue and earnings, driven by improved demand in its bioprocessing and diagnostics segments. The company continues to return cash to shareholders through dividends, and analysts generally maintain positive views on its prospects. Danaher's diversified portfolio in life sciences, diagnostics, and environmental solutions provides exposure to key healthcare and industrial themes, making it a relevant stock for US investors.
Waters Corporation stock (US9418481035): chromatography specialist in focus after latest quarterly results
Waters Corporation, a US-based specialist in analytical instruments and chromatography systems, is in focus after releasing its latest quarterly figures and updating its outlook for 2026. The article details the company's core business model, key revenue drivers, and competitive position within the life science tools industry. It also explains why Waters Corporation is relevant for US investors seeking exposure to the pharmaceutical and biotechnology sectors.
Masimo Corp stock (US5747951003): earnings, Danaher deal and what’s next for the medical-tech specialist
Masimo Corp recently reported strong first-quarter 2026 earnings, surpassing analyst expectations, and its stock has rallied over 30% year-to-date. The medical technology specialist is in the process of being acquired by Danaher, a deal that investors are closely watching for its strategic implications and potential synergies. The article discusses Masimo's core business in patient monitoring, its revenue drivers, market performance, and the competitive landscape for its innovative solutions, especially in light of the impending acquisition.
Solid Q1 and Guidance Underlines Why Danaher Corporation (DHR) is one of Steve Cohen’s Large-Cap Stock Picks
Danaher Corporation (DHR) is a large-cap stock pick of billionaire Steve Cohen, with the company demonstrating strong Q1 2026 results and positive guidance. Danaher is advancing a significant $9.9 billion acquisition of Masimo Corporation, which is expected to close in the second half of 2026, bolstering Danaher's healthcare technology footprint. The company reported a 3.5% year-over-year revenue increase to $6 billion, with adjusted EPS up 9.5%, and upgraded its full-year earnings guidance.
Danaher Corporation $DHR Shares Sold by DNB Asset Management AS
DNB Asset Management AS reduced its stake in Danaher Corporation (NYSE:DHR) by 21.1% in the fourth quarter, selling 34,639 shares. Despite this, Danaher recently beat earnings estimates with an EPS of $2.06 and announced a quarterly dividend of $0.40 per share, maintaining a "Moderate Buy" consensus from analysts. The stock, however, is trading near its 52-week low at $161.95, well below its moving averages.
Assessing Revvity (RVTY) Valuation After Recent Share Price Weakness
Revvity (RVTY) has experienced recent share price weakness, with the stock down 2.5% over the past day and 7% over the past week, prompting a re-evaluation of its valuation. While Simply Wall St's narrative suggests the stock is 21.4% undervalued with a fair value of $119.56 due to expected margin expansion and a shift towards higher-margin offerings, its current P/E ratio is significantly above fair value and industry averages. Investors are encouraged to consider both the discounted cash flow model suggesting a 31.8% discount and the high P/E ratio when making decisions.
Avantor stock (US0543031027): focus shifts to margin recovery after Q1 earnings
Avantor has reported its first-quarter 2026 earnings, showing improving profitability and stabilizing demand in its key markets. The company, a global supplier of life science products and services, is focusing on margin recovery after shifts in demand post-pandemic. This article details Avantor's business model, key revenue drivers, and insights for US investors regarding its market exposure and financial performance.
Fund Update: JANUS HENDERSON GROUP PLC Just Disclosed New Holdings
JANUS HENDERSON GROUP PLC has updated its portfolio based on a 13F disclosure for the report period ending March 31, 2026. Significant changes include a large addition of AstraZeneca (AZN) shares and GEV shares, alongside substantial decreases in holdings of Danaher (DHR), Microsoft (MSFT), Amazon (AMZN), and Praxis Precision Medicines (PRAX). These changes resulted in multi-billion dollar shifts in their portfolio, with a notable almost 900% increase in their AZN position.
Danaher stock (US2358511028): spin-offs reshape the medtech group after latest quarterly numbers
Danaher is undergoing a strategic transformation through spin-offs, adapting to a softer demand environment in its core businesses. The company's first-quarter 2024 results revealed decreased revenue year-over-year but indicated stabilization in bioprocessing, showcasing its strategic shift towards higher-growth life sciences and diagnostics. This article delves into Danaher's business model, revenue drivers, competitive landscape, and its appeal to investors seeking exposure to healthcare innovation through tools and diagnostics.
Danaher (NYSE:DHR) Stock Forecast & Analyst Predictions
This article provides an in-depth analysis of Danaher (NYSE:DHR), including analyst predictions, future growth forecasts, past performance, financial health, and dividend information. It highlights recent financial results, significant company announcements like the Masimo acquisition, and insider trading activities, offering a comprehensive overview for potential investors. The report details Danaher's expected earnings and revenue growth, dividend payouts, and analysts' varying price targets.
iSpecimen stock (US46536T1016): capital raise and Nasdaq compliance in focus
iSpecimen, a biospecimen marketplace, recently secured $2.5 million through a private placement and regained compliance with Nasdaq listing requirements. These actions aim to stabilize the company's financial and listing position as it continues to navigate losses and low share prices. The company's core business involves connecting researchers with human biospecimens, acting as an intermediary in the life sciences services sector.
RBC Capital assumes Danaher stock coverage with outperform rating
RBC Capital has initiated coverage on Danaher Corp. (NYSE:DHR) with an outperform rating and a price target of $200.00, citing confidence in a broadening growth recovery, particularly from bioprocess improvements. The firm projects 6% revenue growth for Danaher in 2027, further bolstered by its anticipated acquisition of Masimo. This positive outlook comes as Danaher's stock trades near its 52-week low, with InvestingPro analysis indicating it is currently undervalued.
GRAIL partners with Epic to broaden Galleri test access across US
GRAIL has announced a partnership with Epic, a leading health record software company, to integrate GRAIL's Galleri multi-cancer early detection test into Epic's electronic health record system. This collaboration aims to streamline the ordering, management, and results delivery of the Galleri test for healthcare providers, thereby broadening its accessibility across health systems in the United States. The integration is expected to enhance clinical workflows and support broader adoption of innovative cancer screening technologies.
